Literature DB >> 21441457

Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.

Silvia Lorenzi1, Fabrizio Mattei, Antonella Sistigu, Laura Bracci, Francesca Spadaro, Massimo Sanchez, Massimo Spada, Filippo Belardelli, Lucia Gabriele, Giovanna Schiavoni.   

Abstract

Cross-presentation is a crucial mechanism for generating CD8 T cell responses against exogenous Ags, such as dead cell-derived Ag, and is mainly fulfilled by CD8α(+) dendritic cells (DC). Apoptotic cell death occurring in steady-state conditions is largely tolerogenic, thus hampering the onset of effector CD8 T cell responses. Type I IFNs (IFN-I) have been shown to promote cross-priming of CD8 T cells against soluble or viral Ags, partly through stimulation of DC. By using UV-irradiated OVA-expressing mouse EG7 thymoma cells, we show that IFN-I promote intracellular Ag persistence in CD8α(+) DC that have engulfed apoptotic EG7 cells, regulating intracellular pH, thus enhancing cross-presentation of apoptotic EG7-derived OVA Ag by CD8α(+) DC. Notably, IFN-I also sustain the survival of Ag-bearing CD8α(+) DC by selective upmodulation of antiapoptotic genes and stimulate the activation of cross-presenting DC. The ensemble of these effects results in the induction of CD8 T cell effector response in vitro and in vivo. Overall, our data indicate that IFN-I cross-prime CD8 T cells against apoptotic cell-derived Ag both by licensing DC and by enhancing cross-presentation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21441457     DOI: 10.4049/jimmunol.1004163

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

Review 1.  Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.

Authors:  Martina Musella; Gwenola Manic; Ruggero De Maria; Ilio Vitale; Antonella Sistigu
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

2.  Autophagy-related protein Vps34 controls the homeostasis and function of antigen cross-presenting CD8α+ dendritic cells.

Authors:  Vrajesh V Parekh; Sudheer K Pabbisetty; Lan Wu; Eric Sebzda; Jennifer Martinez; Jianhua Zhang; Luc Van Kaer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

3.  Long Noncoding RNA Signatures Induced by Toll-Like Receptor 7 and Type I Interferon Signaling in Activated Human Plasmacytoid Dendritic Cells.

Authors:  Rochelle C Joslyn; Adriana Forero; Richard Green; Stephen E Parker; Ram Savan
Journal:  J Interferon Cytokine Res       Date:  2018-09       Impact factor: 2.607

Review 4.  Cross-presentation by dendritic cells.

Authors:  Olivier P Joffre; Elodie Segura; Ariel Savina; Sebastian Amigorena
Journal:  Nat Rev Immunol       Date:  2012-07-13       Impact factor: 53.106

5.  Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Authors:  Katherine A Murphy; Britnie R James; Yue Guan; Donald S Torry; Andrew Wilber; Thomas S Griffith
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

7.  Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.

Authors:  Britnie R James; Erik L Brincks; Tamara A Kucaba; Louis Boon; Thomas S Griffith
Journal:  Cancer Immunol Immunother       Date:  2014-04-08       Impact factor: 6.968

Review 8.  Danger signalling during cancer cell death: origins, plasticity and regulation.

Authors:  A D Garg; S Martin; J Golab; P Agostinis
Journal:  Cell Death Differ       Date:  2013-05-17       Impact factor: 15.828

Review 9.  Interferon regulatory factor 3 in adaptive immune responses.

Authors:  Laure Ysebrant de Lendonck; Valerie Martinet; Stanislas Goriely
Journal:  Cell Mol Life Sci       Date:  2014-05-31       Impact factor: 9.261

Review 10.  Type I interferon response and innate immune sensing of cancer.

Authors:  Mercedes B Fuertes; Seng-Ryong Woo; Byron Burnett; Yang-Xin Fu; Thomas F Gajewski
Journal:  Trends Immunol       Date:  2012-10-31       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.